BF Biosciences Limited (PSX:BFBIO)

Market Cap	14.10B
Revenue (ttm)	5.84B
Net Income (ttm)	447.15M
Shares Out	88.33M
EPS (ttm)	5.52
PE Ratio	28.90
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	381,398
Average Volume	779,997
Open	158.00
Previous Close	157.75
Day's Range	158.00 - 161.50
52-Week Range	76.06 - 253.97
Beta	n/a
RSI	49.33
Earnings Date	Sep 22, 2025

About BF Biosciences

BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic disorders, cardiology, diabetes, anti-obesity, hepatology, gastroenterology, chronic kidney diseases, dermatology, antifungal treatments, antibiotics, antivirals, rheumatoid arthritis, nephrology, and oncology. It also provides injectables in vials, ampoul...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 535
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: BFBIO

Financial Performance

In 2025, BF Biosciences's revenue was 5.84 billion, an increase of 59.55% compared to the previous year's 3.66 billion. Earnings were 447.15 million, an increase of 16.02%.